acu193
mAbexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 21, 2021 (NCT04931459)
Timeline
Indications
Studied for
Mechanism of action
NAE1 antagonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314772 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06511570 | Phase 1 | Jun 25, 2024 | Acumen Pharmaceuticals |
| NCT06335173 | Phase 2 | Feb 29, 2024 | Acumen Pharmaceuticals |
| NCT04931459 | Phase 1 | Jun 21, 2021 | Acumen Pharmaceuticals, National Institute on Aging (NIA) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Acumen Pharmaceuticals | For profit | 3 | 3 | 2 | 2021 |
| National Institute on Aging (NIA) | Government | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1